CollPlant Biotechnologies (NASDAQ:CLGN – Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($1.89) earnings per share for the quarter, FiscalAI reports. The company had revenue of $0.11 million during the quarter. CollPlant Biotechnologies had a negative return on equity of 218.81% and a negative net margin of 683.68%.
CollPlant Biotechnologies Stock Performance
NASDAQ:CLGN traded down $0.01 during mid-day trading on Wednesday, reaching $3.78. The stock had a trading volume of 10,821 shares, compared to its average volume of 125,796. The firm has a 50 day moving average price of $3.42 and a two-hundred day moving average price of $3.90. The stock has a market capitalization of $7.14 million, a P/E ratio of -0.26 and a beta of 1.79. CollPlant Biotechnologies has a one year low of $2.64 and a one year high of $26.80.
Analysts Set New Price Targets
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of CollPlant Biotechnologies in a research report on Friday, September 4th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, CollPlant Biotechnologies presently has an average rating of “Reduce” and an average price target of $120.00.
About CollPlant Biotechnologies
CollPlant Biotechnologies Ltd. is an Israel-based regenerative medicine company developing products based on recombinant human collagen (rhCollagen). The company produces rhCollagen using genetically engineered tobacco plants, an approach designed to create collagen with consistent properties and without relying on animal or human tissues.
CollPlant’s technology is intended for use in tissue regeneration, medical aesthetics, wound care and organ manufacturing. Its product portfolio includes rhCollagen-based biomaterials and bioinks for three-dimensional bioprinting, which are designed to support the development of implants, tissue scaffolds and other regenerative medicine applications.
Founded in 2004 and headquartered in Rehovot, Israel, CollPlant has pursued collaborations and licensing arrangements with companies in the medical technology and bioprinting industries.
Further Reading
- Five stocks we like better than CollPlant Biotechnologies
- Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors?
- O’Reilly Automotive’s Stock Slump Hides a Stronger Business
- McDonald’s Stock Slump Makes Its AI Pricing Bet Even Riskier
- Broadcom’s AI Growth Story Faces a $161 Billion Anthropic Test
Receive News & Ratings for CollPlant Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CollPlant Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
